After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
AbbVie forges $3.9 billion oncology alliance with GenmabAbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed Share XAbbVie forges $3.9 billion oncology alliance with Genmabhttps://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/
Saunders steps aside as AbbVie closes in on Allergan mergerThe US competition regulator has finally approved the $63 billion takeover of Allergan by AbbVie, but only by Share XSaunders steps aside as AbbVie closes in on Allergan mergerhttps://pharmaphorum.com/news/saunders-steps-aside-as-abbvie-closes-in-on-allergan-merger/
AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalAbbVie and Johnson & Johnson’s Imbruvica is already a mainstay of chronic lymphocytic leukaemia (CLL) therapy, but can Share XAbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalhttps://pharmaphorum.com/news/abbvie-jj-embed-imbruvica-deeper-in-cll-therapy-with-new-approval/
Thousands sign up to large-scale COVID-19 trial in UKThousands of patients have signed up in a few days to support a large-scale NHS trial for potential Share XThousands sign up to large-scale COVID-19 trial in UKhttps://pharmaphorum.com/news/thousands-sign-up-to-large-scale-covid-19-trial-in-uk/
AbbVie won’t enforce patents for COVID-19 drug candidate KaletraAbbVie has said it won’t defend patent rights to its HIV therapy Kaletra in the hope that it Share XAbbVie won’t enforce patents for COVID-19 drug candidate Kaletrahttps://pharmaphorum.com/news/abbvie-wont-enforce-patents-for-covid-19-drug-candidate-kaletra/
New combination trial firms up Venclexta’s prospects in AMLAbbVie and Roche have been thrown a lifeline for their Venclexta drug in acute myeloid leukaemia (AML), just Share XNew combination trial firms up Venclexta’s prospects in AMLhttps://pharmaphorum.com/news/new-combination-trial-firms-up-venclextas-prospects-in-aml/
AbbVie’s Kaletra doesn’t work in COVID-19, say Chinese scientistsA clinical trial of AbbVie’s HIV therapy Kaletra conducted by researchers in China has undermined hopes it could Share XAbbVie’s Kaletra doesn’t work in COVID-19, say Chinese scientistshttps://pharmaphorum.com/news/abbvies-kaletra-doesnt-work-in-covid-19-say-chinese-scientists/
AbbVie/Allergan merger cleared in EU with brazikumab sell-offAbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of Share XAbbVie/Allergan merger cleared in EU with brazikumab sell-offhttps://pharmaphorum.com/news/abbvie-allergan-merger-cleared-in-eu-with-brazikumab-sell-off/
